Emerald secures £1.4m pre-seed funding from Boost Capital Partners to expand its preventive health platform.
The funding round was led by Boost Capital Partners and will support UK expansion and proprietary coaching protocols.
Emerald provides a preventive health platform that unifies fragmented biomarkers and pairs members with dedicated general practitioners. The service combines comprehensive blood testing with continuous monitoring and clinical oversight.
Emerald has raised £1.4m in pre-seed funding to support its UK expansion and the launch of new coaching protocols. The investment round was led by Boost Capital Partners, with additional backing from Granatus Ventures, angel investors, and tech founders including Mark Fountain. The fresh capital follows the company securing registration with the Care Quality Commission to operate as a fully fledged medical provider.
From the founder
"Right now, the trade-off is access versus quality. Unmoderated AI can scale access but can miss context, and when it’s wrong the cost can be high. Clinicians offer quality, but they can’t see everyone at once. We’re building the future where doctors, AI tools, and a unified data layer work together to reach more people with safer, higher-quality guidance."
Alexander Badalyan
Co-founder and CEO at Emerald
Investor perspective
"We believe that the next trillion dollar company will be one that gives people back control over their health. This can only be achieved with the right combination of an engaging product, a scientific approach and the capabilities to aggregate, gather, integrate and present health data in a comprehensive way for their users."
Benjamin Torrero
Representative, Boost Capital Partners
Use of funds
- 01Expand into international markets